Text Size
Trial record 5 of 6 for:    Open Studies | "Photorefractive Keratectomy"
Previous Study | Return to List | Next Study

The Effect of Gabapentin (Neurentin) and Pregabalin (Lyrica) in Pain Reduction After Photorefractive Keratectomy (PRK)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified March 2010 by Shaheed Beheshti Medical University.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Shaheed Beheshti Medical University
ClinicalTrials.gov Identifier:
NCT01122004
First received: April 12, 2010
Last updated: May 10, 2010
Last verified: March 2010
History of Changes
  Purpose

The studied patients will be given randomly one of three following drugs1:Gabapentin2: Pregabalin or placebo for 3 days after Photorefractive keratectomy surgery. The pain will be measured based on visual analog scale(VAS) on the day of operation and on the 3 rd day (morning, evening) and then compared among three groups.


Condition Intervention Phase
Refractive Errors
 Drug: Pregabalin
 Phase 1

Study Type: Interventional
Study Design: Primary Purpose: Treatment

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Shaheed Beheshti Medical University:

Primary Outcome Measures:
  • pain degree based on visual analog scale(VAS)

Arms Assigned Interventions
Active Comparator: Gabapentin Drug: Pregabalin
Active Comparator: Pregabalin Drug: Pregabalin

  Eligibility

Ages Eligible for Study:   17 Years and older
Genders Eligible for Study:   Both
Criteria

Inclusion Criteria:

  • patients candidate for PRK, 17<age<70

Exclusion Criteria:

  • use of any systemic analgesic drugs, drug intolerance, need of systemic or topical administration of NSAIDs or eye drops for allergy and glaucoma, dry eyes, pregnancy, breast feeding
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01122004

Contacts
Contact: Amir faramarzi, MD +982122585952

Locations
Iran, Islamic Republic of
Ophthalmic Research Center Recruiting
Tehran, Iran, Islamic Republic of, 166666
Contact: Amir Faramarzi, MD         labbafi@hotmail.com    
Sponsors and Collaborators
Shaheed Beheshti Medical University
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT01122004     History of Changes
Other Study ID Numbers: 8877
Study First Received: April 12, 2010
Last Updated: May 10, 2010
Health Authority: Iran: Ethics Committee

Additional relevant MeSH terms:
Refractive Errors
Eye Diseases
Gabapentin
Pregabalin
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Pharmacologic Actions
Central Nervous System Agents
Therapeutic Uses
Anticonvulsants
Antiparkinson Agents
 Anti-Dyskinesia Agents
Calcium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Cardiovascular Agents
Anti-Anxiety Agents
Tranquilizing Agents
Central Nervous System Depressants
Psychotropic Drugs
Excitatory Amino Acid Antagonists
Excitatory Amino Acid Agents
Neurotransmitter Agents
Antimanic Agents

ClinicalTrials.gov processed this record on May 16, 2013